ous public debate (initially in Europe, but now widespread) concerning the potential effect of human insulin on hypoglycemic responses in IDDM and the research that preceded and followed it. Indeed, their results, with a dissociation between symptomatic and objective responses, are very similar to those of one of these earlier studies (3) , and it may be helpful to examine the position of that study in the original debate.
The initial studies of the actions of human insulin were published in the early 1980s as part of a series of planned investigations for a new drug. In these early laboratory studies of hypoglycemia induced by human (usually biosynthetic) insulin in normal volunteers, diminished epinephrine (4-6) and norepinephrine (5,7) responses were described, while glucagon, prolactin, growth hormone, and cortisol responses were found to be diminished (4), unaffected (8, 9) , or increased (5, 8) and glucose recovery was slower (5, 8) , identical (4, 10) , or faster (9) . Symptoms, rarely measured quantitatively in these early studies, were said to be less (4, 5) . Parenthetically, it was suggested at the time that diminished glucagon and cortisol responses, in particular, might be of benefit in the struggle for better diabetic control. Most of these studies were small and usually used an intravenous bolus of insulin to induce a hypoglycemic challenge. Details of statistical analyses, randomization procedures, and intervals between repeated testing are often lacking. Later studies were prompted by the clinical questions that had arisen about hypoglycemia on human insulin. They have, in general, been larger and used controlled and reproducible hypoglycemic stimuli in subjects with IDDM. By and large, these more sophisticated studies have found no effect of insulin species on the magnitude of hormonal responses or symptoms during hypoglycemia (11) (12) (13) (14) (15) (16) and accelerated glucose recovery with human insulin (11) . It might perhaps be argued that IDDM subjects have a more heterogenous response to hypoglycemia, making identification of small differences in responses difficult to detect, but it is undoubtedly this that is the population at risk and the one where relevant studies eventually had to be done. The study that found, as in Meneilly et al.'s NIDDM patients, that subjects reported fewer symptoms at a blood glucose level of 3.3 mmol/1 during human insulin hypoglycemia, despite no effect on hormonal and cognitive function responses (3), was not duplicated elsewhere, and a larger study in which prior glycemic experience was carefully controlled found no such effect (16) . No study has found defects in counterregulatory responses to the hypoglycemia of human insulin comparable DIABETES, VOL. 44, MARCH 1995 to those found in other hypoglycemia-unaware groups (17) (18) (19) .
Results of attempts to look formally at the clinical experience of hypoglycemia in patients converted to the use of human insulin have left people equally divided. The Swiss investigators who first described serious hypoglycemia in their IDDM patients coincident with their conversion to human insulin (20) later found an excess of human insulin users among patients admitted to a hospital with severe hypoglycemia (21) and reported an increase in the incidence of severe hypoglycemia that paralleled the increased market share of human insulin products (22) . Other countries could not confirm this finding (23, 24) , and there is a possibility that improved diabetes control contributed to the Swiss phenomena. Two additional Swiss studies presented evidence that symptoms of hypoglycemia differed in patients using human insulin (25, 26) : one found that "loss of concentration" moved from fourth to first place in patient rankings of the symptoms most important to them in detecting a falling blood glucose concentration (25) . The first seven symptoms were, however, the same on either insulin, and there was no increase in the frequency of severe hypoglycemia. In a study from Scotland, the 6% of patients who retrospectively described loss of hypoglycemic awareness on conversion to human insulin (27) were not many more than might have been expected to be losing awareness as a result of increasing disease duration (28) . Negative studies of the frequency of severe hypoglycemia on the different insulins (24, 29, 30) have been criticized for being retrospective. Prospective studies, both small (16) and not so small (31, 32) , have been unable to find differences in the frequency or experience of hypoglycemia on human and porcine insulins used blindly. However, it has been calculated that to provide a definitive negative answer, a sample size of up to 10,000 patients would be required; such a study is unlikely to be done.
If there are no detectable differences in the physiological responses to hypoglycemia induced by human insulin, and small-scale studies cannot find any clinical effect, why has the anxiety about human insulin not been resolved? It remains possible that an effect too small to be detected by current research may be enough to trigger a problem in already susceptible patients, such as those with long-duration diabetes or very tight glycemic control (28, 2) . Such patients may develop problems with hypoglycemia coincident with conversion to human insulin, especially if, as with many, the conversion included an intensification of insulin regimen. Alternatively, these patients may be more susceptible to an otherwise trivial effect of altering insulin species. Diminished epinephrine responses with human insulin hypoglycemia have been described in some subjects with longbut not short-duration diabetes, for example (11), although no effect was found in formal studies of patients who reported hypoglycemia unawareness that they themselves had attributed to conversion to human insulin use (15, 16) . There are pharmacokinetic differences between the different insulins (33) that, while apparently of little overall clinical effect (10), may be problematic in a susceptible patient. The critical amino acid that distinguishes human insulin is not located on those parts of the insulin molecule involved in receptor binding and insulin action but may inhibit the aggregation of insulin molecules into polymers (33), which would be expected to speed absorption from subcutaneous injection sites. The human insulin molecule is also less lipid soluble (34) , which may affect its ability to enter the brain (35) , although there is no evidence of any differential effect of human insulin on cognitive function during hypoglycemia (15, 16) . Human insulins, injected subcutaneously, have a slightly faster onset and shorter duration of action than their animal equivalents (33). While this does not appear to be of clinical relevance (36) (and may indeed be advantageous for the meal-related regular insulin to the extent that current research is working on insulins with even less tendency to aggregate), it may render the NPH and lente insulins too short and "peaked" in their effect to give optimal insulin levels in the morning while avoiding hyperinsulinemia at night (37-39). These differences may be subtle, but it is not perhaps surprising that some patients will do better on one insulin than another. It is known that one moderate hypoglycemic episode may prejudice responses to subsequent episodes (40, 41) .
The authors of the early studies of human insulin recommended that conversion to the use of human insulin should be carefully monitored and changes in doses and/or injection times should be considered. These recommendations, at least in some parts of Europe, were seen as much in the breach as in the honoring, because patients were switched almost en masse and often without consultation. The magnitude of the changeover, seen in retrospect as having been driven as much by economic as by clinical considerations, undoubtedly contributed to the heat of the debate.
We are left then, in IDDM, with the majority of formal investigations reporting that human insulin does not specifically alter the physiological responses to hypoglycemia induced in a laboratory setting and does not have any detectable effect on the frequency of clinical hypoglycemia. Where does this leave the patients, some of whom undoubtedly do report problematic hypoglycemia on conversion to human insulin and many more of whom have become seriously worried by the possibility that they might? If, as scientists, we conclude that human insulin does not in itself affect the physiological responses to hypoglycemia, then as clinicians we must respond to the experiences of the people using it, especially perhaps because the anticipated theoretical advantages of human insulin have not really materialized. Human insulin is not markedly less immunogenic than highly purified porcine equivalents (38) and, although now competitive, it has not become cheaper. In the absence of any contraindication to the use of highly purified animal insulins, these should be available for those patients who feel more secure using them, and patients who believe their problematic hypoglycemia is related to human insulin usage should be allowed to convert back to their previous insulin. The imperfections of all currently available exogenous insulins must be recognized, and while the search for the perfect insulin substitute continues, a variety of insulins for the variety of patients is desirable. But it is very dangerous to assume that all (or even most) problems with hypoglycemia can be resolved by resumption of animal insulins. Perhaps the most telling evidence we have that insulin species itself is not a direct cause of hypoglycemia unawareness is the evidence that symptomatic responses can be restored to patients with documented failure of counterregulation without the need to change the insulin species back again (42, 43) .
Is the debate now to be rehearsed for patients with NIDDM? As already discussed, the study from Dr. Meneilly's group is typical of the many done in IDDM subjects that have been unable to settle the question and is matched by at least the one study with a lowering of the glucose level at which symptoms of hypoglycemia first occur during acute hypoglycemia induced with human rather than animal insulin. The change in glucose threshold for symptom generation is small (3.6-3.3 mmol/1 for autonomic and 3.3-3.0 mmol/1 for neuroglycopenic symptoms), and the usual, presumably protective, hierarchy of symptom generation preceding loss of cognitive function as blood glucose concentrations fall was maintained, so the potential clinical significance of this finding is not clear. And as with any study, flaws in the study design can be criticized: most notably, the failure to exclude asymptomatic hypoglycemia in the 24 h preceding each study, a question raised by the high cortisol levels at the beginning of the human insulin arm and one that could undoubtedly affect the results obtained (40, 41) . On the other hand, any diminution in subjective awareness to hypoglycemia is to be regarded with suspicion. The data of Meneilly et al. (1) need to be duplicated in a study where preceding glycemic experience is known to be comparable.
Meanwhile, for the clinician contemplating starting insulin therapy in NIDDM patients, it is relevant to recall that there have been no reports of problems with hypoglycemia for people using human insulins from the beginning (43, 44) . If this is true, human insulin may be an appropriate insulin to use in NIDDM patients not previously exposed to insulin therapy, that is, at least until the new biosynthetic insulins, with their tailor-made action profiles, are ready for use! In the meantime, there are some very important lessons to be learned from the furor that has erupted over human insulin in parts of Europe. There is little doubt that rational debate and scientific evaluation have been hampered by sensationalist publicity and threats of litigation and intransigence from both human insulin's supporters and detractors. It is likely that the last was conceived in the forceful way in which the new insulins were introduced and then compounded by the involvement of lawyers and the failure of some health care professionals to take adequate notice of the fears of some of their patients. Whatever the final judgment on human insulin's use in NIDDM, I hope that it is reached in a more dignified way.
